Epidemiology of vancomycin-resistant enterococci with reduced susceptibility to daptomycin

Infection Control and Hospital Epidemiology

Volumn 33, Issue 12, 2012, Pages 1250-1254

  Judge, Theresa ^a   Pogue, Jason M ^a   Marchaim, Dror ^b   Ho, Kevin ^b   Kamatam, Srinivasa ^b   Parveen, Shakila ^b   Tiwari, Namita ^b   Nanjireddy, Priyanka ^b   Bheemreddy, Suchitha ^b   Biedron, Caitlin ^b   Lepakshi Reddy, Sagar Mallikethi ^b   Khammam, Vijaykumar ^b   Chalana, Indu K ^b   Tumma, Rajachendra Shekher ^b   Collins, Vicki ^b   Yousuf, Adnan ^b   Lephart, Paul R ^a   Martin, Emily T ^b   Rybak, Michael J ^b   Kaye, Keith S ^b   Hayakawa, Kayoko ^b   more..

^a DETROIT MEDICAL CENTER   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE; AMPICILLIN; BETA LACTAM; BETA LACTAMASE INHIBITOR; CARBAPENEM; CEPHALOSPORIN; CEPHALOSPORIN DERIVATIVE; CLINDAMYCIN; DAPTOMYCIN; GENTAMICIN; LINEZOLID; MACROLIDE; METRONIDAZOLE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; STREPTOMYCIN; SULFAMETHOXAZOLE; TETRACYCLINE DERIVATIVE; TRIMETHOPRIM; VANCOMYCIN;

ADULT; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATION; CASE CONTROL STUDY; COMORBIDITY; CONTROLLED STUDY; EPIDEMIOLOGY; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MALE; RETROSPECTIVE STUDY; RISK FACTOR; VANCOMYCIN RESISTANT ENTEROCOCCUS;

ADULT; AGED; ANTI-BACTERIAL AGENTS; CASE-CONTROL STUDIES; CEPHALOSPORINS; COMORBIDITY; DAPTOMYCIN; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; FEMALE; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; IMMUNOSUPPRESSION; MALE; METRONIDAZOLE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; STATISTICS, NONPARAMETRIC; VANCOMYCIN; VANCOMYCIN RESISTANCE;

EID: 84869199378     PISSN: 0899823X     EISSN: None     Source Type: Journal    
DOI: 10.1086/668438     Document Type: Article

References (9)

1. Canton R, Ruiz-Garbajosa P, Chaves RL, Johnson AP. A potential role for daptomycin in enterococcal infections: what is the evidence? J Antimicrob Chemother 2010;65:1126-1136.
2. Kelesidis T, Humphries R, Uslan DZ, Pegues DA. Daptomycin nonsusceptible enterococci: an emerging challenge for clinicians. Clin Infect Dis 2011;52:228-234.
3. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-383.
4. Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobia Susceptibility Testing: Nineteenth Informational Supplement. Wayne, PA: CLSI; 2009. CLSI document M100-S19.
5. Kamboj M, Cohen N, Gilhuley K, Babady NE, Seo SK, Sepkowitz KA. Emergence of daptomycin-resistant VRE: experience of a single institution. Infect Control Hosp Epidemiol 2011;32:391-394.
6. Munoz-Price LS, Lolans K, Quinn JP. Emergence of resistance to daptomycin during treatment of vancomycin-resistant Entero-coccus faecalis infection. Clin Infect Dis 2005;41:565-566.
7. Arias CA, Panesso D, McGrath DM, et al. Genetic basis for in vivo daptomycin resistance in enterococci. N Engl J Med 2011; 365:892-900.
8. Dade Behring. MicroScan Dried Gram Positive Panels 2011-04 Enterococcus faecium with Reduced Susceptibility to Daptomycin. Technical Support Bulletin 182. Sacramento, CA: Dade Behring, 2011.
9. Palavecino EL, Schoppe CH. Discrepancies between daptomycin susceptibility results by MicroScan panel PC29 and by E test in S. aureus and enterococci. The 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Chicago; 2011.